Varian, Boston Scientific FDA Approvals Aid Q1 Double-Digit Stock Gains
This article was originally published in The Gray Sheet
Executive Summary
Varian Medical Systems' receipt of 510(k) clearance for its On-Board Imaging tumor tracking accessory helped the radiation oncology firm's stock soar 24.9% in the first quarter - jumping $17.21 to close at $86.31
You may also be interested in...
Lehman Brothers Global Healthcare Conference In Brief
Gen-Probe pursues HPV assay: Human papillomavirus test technology access is being sought by the company, which has held discussions with "three or four" developers thus far about potential "ways to collaborate," CFO Herm Rosenman reported March 3 at the Lehman Brothers Global Healthcare Conference in South Beach, Florida. HPV market participants include Digene (DNAwithPap) and Roche (Amplicor). Should discussions be unsuccessful, Gen-Probe "will continue to engineer our own" intellectual property to work around current barriers to entering the market, according to Rosenman. Gen-Probe projects $235 mil.-$245 mil. in revenue this year, supported by strong sales of its Tigris automated nucleic acid test platform (1"The Gray Sheet" Jan. 5, 2004, p. 5)...
Cordis Parries Taxus Approval Thrust With REALITY Procedure Success Data
Post-market surveillance of Boston Scientific's Taxus paclitaxel-eluting stent will cover over 3,500 patients and include five-year follow-up on more than 1,500 patients treated in pre-market trials
Cordis Recruits Guidant To Block Taxus, Develop Combined Delivery System
Johnson & Johnson/Cordis is betting that its drug-eluting stent marketing alliance with Guidant will allow it to match Boston Scientific's sales presence in U.S. cath labs